A groundbreaking study from the University of Auckland is offering new hope for people affected by Parkinson’s disease and multiple system atrophy (MSA)—two neurodegenerative disorders that are notoriously difficult to tell apart in their early stages.
Parkinson’s and MSA often begin with similar symptoms: tremors, stiffness, and balance issues. But while Parkinson’s typically progresses slowly and responds to certain medications, MSA is far more aggressive and doesn’t respond to the same treatments. Misdiagnosis can lead to ineffective or even harmful care. Until now, distinguishing between the two has required invasive procedures or has only been possible after death through brain tissue analysis.
That’s where this new research comes in. Scientists at the University of Auckland’s Centre for Brain Research, in collaboration with the University of Sydney, studied donated brain tissue and found a key difference: the way a protein called α-synuclein clumps in the brain. In MSA, α-synuclein accumulates in much higher amounts and in different patterns than in Parkinson’s. This discovery opens the door to developing non-invasive diagnostic tests—such as nasal swabs or blood tests—that could detect these protein patterns while a person is still alive.
Early and accurate diagnosis is critical. It allows patients and their families to plan for the future, access the right treatments, and avoid unnecessary medications. For researchers, it also means better-targeted clinical trials and a clearer path toward finding a cure. Dr. Maurice Curtis, co-director of the Centre for Brain Research, emphasized the importance of this work: “This is a major step forward in our ability to diagnose and eventually treat these devastating diseases.”
The team is now working on translating their findings into practical diagnostic tools. If successful, this could revolutionize how we detect and manage neurodegenerative diseases—not just Parkinson’s and MSA, but potentially others as well. This research is a powerful reminder of the value of brain donation and international collaboration in advancing medical science. It also highlights the importance of investing in early detection, because when it comes to brain health, timing is everything.